[Effects of nateglinide in impaired glucose tolerance subjects].
Hirose
Takahisa
T
Metabolism and Endocrinology, Department of Medicine, Juntendo University School of Medicine.
D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D002986:Clinical Trials as Topic; D003510:Cyclohexanes / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000209:etiology / Q000517:prevention & control; D018149:Glucose Intolerance / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy* / Q000209:etiology; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000378:metabolism*; D007333:Insulin Resistance; D000078790:Insulin Secretion; D000077715:Nateglinide; D009765:Obesity / Q000150:complications / Q000503:physiopathology; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D019518:Postprandial Period; D012307:Risk Factors
D003510:Cyclohexanes; D007004:Hypoglycemic Agents; D007328:Insulin; D000077715:Nateglinide; D010649:Phenylalanine